Prof Research published a new Market report on DPP IV Inhibitor (DPP-4 Inhibitor) Market. It presents the largest 12 manufacturers in DPP IV Inhibitor (DPP-4 Inhibitor) Market. The report is a professional and in-depth study on the current state of the global Inks market with a focus on the Chinese market. The report provides key statistics on the market of DPP IV Inhibitor (DPP-4 Inhibitor). This report covers 11 individual products:  Sitagliptin, Linagliptin, Vildagliptin, Saxagliptin, Alogliptin, Gemigliptin, Anagliptin, Teneligliptin, Trelagliptin, Evogliptin and Omarigliptin. It is a valuable source of guidance and direction for companies and individuals interested in DPP IV Inhibitor (DPP-4 Inhibitor) industry.

The product of MSD include Januvia (sitagliptin) 100mg, 50mg, 25mg tablets and Janumet or Janumet XR (sitagliptin/metformin). It is the largest manufacturer and market share is about 50%.

The product of Boehringer Ingelheim include Trajenta®/Tradjenta®/Trazenta®/Trayenta® (linagliptin) and Jentadueto®/Trayenta Duo®/Trajenta Duo®/Trajentamet® (linagliptin/metformin). It is the second largest producer and their market share is about 16%.

Novartis's product is Galvus (Vildagliptin) and their market share is about 12%.

AstraZeneca produce Onglyza (saxagliptin) and has 5% market share.  Eli Lilly (Trajenta®/Tradjenta®/Trazenta®/Trayenta® (linagliptin)

Jentadueto®/Trayenta Duo®/Trajenta Duo®/Trajentamet® (linagliptin/metformin) ) and Takeda (Nesina (Alogliptin) and combos Kazano and Oseni) also have 5% market share.